LJUBLJANA (Slovenia), March 20 (SeeNews) – Slovenian pharmaceuticals producer Krka [LJE:KRKG] recorded a consolidated net profit of 244.3 million euro ($263.7 million) in 2019, up 40% on the year, the company said, citing unaudited data.
Consolidated revenue increased to 1.49 billion euro from 1.33 billion euro in 2018, Krka said in a bourse filing on Thursday.
The 2019 operating profit of the Krka group amounted to 274.2 million euro, up 18% year-on-year, while profit before tax totalled 284.4 million euro, up 40%.
Krka's consolidated EBITDA amounted to 385.4 million euro in 2019, up 12% year-on-year.
The Krka group allocated 112.6 million euro to investments last year, of which 90.5 million euro to the controlling company.
Eastern Europe generated the highest sales within the group, of 481.2 million euro, or 32.3% of total sales. Sales in Eastern Europe rose 17% on the year in 2019.
Next came Central Europe, where sales revenue increased 7% to 339.6 million euro, or 22.8% of total sales.
West Europe followed with sales of 336.1 million euro, up 17% over 2018 and 22.6% of total.
Sales in Southeast Europe grew 9% to 191.3 million euro, whereas sales in the Overseas Markets segment increased 12% to 48.6 million euro.
Sales in Slovenia increased to 92.4 million euro, up 3% on the year. They contributed 6.2% of total Krka group sales.
Krka's shares closed 1.01% higher at 60.2 euro on the Ljubljana Stock Exchange on Thursday in a turnover of 401,970 euro, the highest among the blue chips, bourse data showed.
($ = 0.9263 euro)
KRKA d.d. is among the biggest companies in SEE. You can download our SEE Top 100 ranking
here or subscribe to our free Top 100 newsletter
here